China Jieya releases 2024 performance forecast

    Tongling Jieya Biotechnology Co., Ltd. has released its unaudited 2024 annual performance forecast, estimating a net profit attributable to shareholders of approximately 15 to 22.5 million yuan for the year, representing a significant year-on-year decline. The primary reasons for this decrease include a sharp drop in the overall gross profit margin due to intense market competition and a substantial increase in impairment provisions.